Inhibition of CD38 activity blocked the homing of CLL cells from the bloodstream to lymphoid organs, suggesting that targeting CD38 could be a potential therapeutic strategy to inhibit CLL proliferation [98]. Here, CD38 is linked to B-cell chronic lymphocytic leukemia.